Table 4.

Virus-vector-based vaccines against ZIKV infection.

Vaccine’s Name or Component	Immunogenicity in the Induction of Immune Responses	Animal Model	Vaccine Doses	Administration Route	Virus Challenged	Ref.
Ad4-prM-E and Ad5-prM-E	Ad5-prM-E vaccination induced both humoral and T-cell responses, while Ad4-prM-E induced only a T-cell response.	C57BL/6 mice	Two doses at three-week interval	i.m.	Puerto Rico strain PRVABC59	[39]
hAd5-prM-E	Induced both cell-mediated and humoral immune responses, which conferred protection against a ZIKV challenge	C57BL/6 mice and Ifnar1−/− mice	Single dose	i.n.	Puerto Rico strain PRVABC59	[41]
Ad5-Sig-prM-Env (prM-E) and Ad5-Env (E)	Both vaccines elicited robust humoral and cellular immune responses in immunocompetent BALB/c mice, as well as in A129 mice, but Ad5-Sig-prM-Env-vaccinated mice resulted in significantly higher ZIKV-specific neutralizing antibody titers and lower viral loads than Ad5-Env-vaccinated mice.	BALB/c mice and A129 mice	Single dose	i.m.	Puerto Rico strain PRVABC59	[42]
ChAdOx1	Induced high levels of protective responses in challenged mice	BALB/c mice	Single dose	i.m.	Brazilian ZIKV	[43]
RhAd52-prMEnv	Induced ZIKV-specific neutralizing antibodies in rhesus monkeys; antibodies sufficient for protection against ZIKV challenge in mice	Rhesus monkeys and BALB/c mice	Single dose	i.m.	Brazilian ZIKV and Puerto Rico strain PRVABC59	[44]
rVSV-prM-E-NS1	Induced ZIKV-specific antibody and T-cell immune responses that conferred partial protection against ZIKV infection	A129 mice and BALB/c mice	Single dose	i.n.	Cambodian strain FSS13025	[45]
VSV-Capsid and VSV-ZikaE260-425	Both vaccines induced strong ZIKV-specific humoral responses in immunized BALB/c mice, but VSV-Capsid immunization elicited significantly higher levels of IFN-γ+ CD8+ and CD4+ T-cells than that of VSV-ZikaE260-425 vaccine.	BALB/c mice	Single dose	i.n.	Puerto Rico strain PRVABC59	[46]

Note: i.m., intramuscular injection; i.n., intranasal injection.